The global biosurgery market reached a value of US$ 12.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2027, exhibiting a CAGR of 6.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Biosurgery is a medical procedure that involves the use of natural, synthetic or semi-synthetic materials to seal surgical incisions and wounds. It is widely used for preventing excessive blood loss, providing adhesion for wound or tissue sealing and repairing damaged tissues and bones. Biosurgeries are usually conducted through various hemostatic, sealant, soft tissue repair, bone graft substitute, adhesion prevention and staple line reinforcement products. They also utilize natural allografts, cultured epithelial autografts and xenografts for minimizing intra and post-operative complications and promoting faster recovery of the patients. As a result, they are widely used for neurological, cardiovascular, orthopedic, spinal, thoracic and reconstruction surgeries.

Biosurgery Market Trends:
The increasing prevalence of musculoskeletal disorders that require treatment through surgical procedures is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more prone to osteoporosis and other chronic medical ailments, is providing a thrust to the market growth. Patients and healthcare providers are widely adopting biosurgeries for effective blood loss management in patients through minimally invasive (MI) hemostatic agents and surgical sealants in place of traditionally used sutures and staples. In line with this, the rising incidents of sports-related injuries and accidental traumas is also contributing to the growth of the market. Additionally, various technological advancements, such as the development of plasma-based, multi-functional and multi-use products for biosurgeries, are favoring the growth of the market. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biosurgery market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, source, application and end user.

Breakup by Product:

Bone-Graft Substitutes
Soft-Tissue Attachments
Hemostatic Agents
Surgical Sealants and Adhesives
Adhesion Barriers
Staple Line Reinforcement

Breakup by Source:

Natural/Biologics Products
Synthetic Products

Breakup by Application:

Orthopedic Surgery
General Surgery
Neurological Surgery
Cardiovascular Surgery
Gynecological Surgery
Others

Breakup by End User:

Hospitals
Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc.

Key questions answered in this report:
How has the global biosurgery market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global biosurgery market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the source?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global biosurgery market and who are the key players?
What is the degree of competition in the industry?